Patients diagnosed with PCa at second biopsy showed overexpression of PTX3/C1q deposits, increased expression of C3a and C5a receptors, inactivation of the terminal complement complex C5b-9, and a significant increase of complement inhibitor CD59. The gene discussed is C3; the disease is posterior cortical atrophy.